Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus PD-1 monoclonal antibody in elderly AML/MDS-EB1/2
ChiCTR2000034927Phase 4Recruiting
- Sponsor
- Chengdu Shangjin Nanfu Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Azacitidine + PD-1 monoclonal antibody with Azacitidine monotherapy (2 arms). Primary endpoint: Efficacy of azacitidine combined with PD-1 monoclonal antibody. Started Aug 2020; status: recruiting.
02
Drugs
azacitidinePD-1 Monoclonal Antibody
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2000034927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034927.